WebMar 22, 2013 · This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. WebFeb 3, 2024 · Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with ...
Post-Transplant Maintenance Treatment Options in …
WebWayne Kuznar. Orlando, FL—A conditioning regimen before autologous hematopoietic stem-cell transplant (HSCT) consisting of carfilzomib (Kyprolis) plus high-dose … WebObjective: We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. Methods: This randomised, open-label, phase 2 trial included patients … scotchie\\u0027s custom cakes
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa ... - Nature
WebJan 27, 2024 · Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma, according to researchers. Results from the ATLAS trial showed that carfilzomib plus lenalidomide and dexamethasone significantly prolongs progression … WebApr 9, 2024 · before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open - label, phase 3 study. Lancet 394 , 29 – 38 (2024). WebDec 20, 2024 · Source Reference: Yong K, et al "Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in ... scotchie\\u0027s custom cakes winter park